This still provides a potential for an autologous therapeutic strategy for inflammatory diseases such as RA or during aging, with modification of patients’ hematopoietic stem cells to overexpress TTP, which leads to their progeny also expressing higher levels of TTP, and even if these differentiated cells are present in small numbers, they may provide long-term relief of symptoms and signs associated with chronic inflammatory conditions. The gene discussed is ZFP36; the disease is rheumatoid arthritis.